24.33

3.09% 0.73

Catalyst Pharmaceuticals Inc (CPRX)

Overview News Price History Option Chain Financials Why CPRX Down? Discussions Forecast

Catalyst Pharmaceuticals Inc stock is traded at $24.33, with a volume of 1.16M. It is up +3.09% in the last 24 hours and up +8.86% over the past month. Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).

Previous Close:

$23.60

Open:

$23.67

24h Volume:

1.16M

Relative Volume:

0.97

Market Cap:

$2.99B

Revenue:

$460.48M

Net Income/Loss:

$142.80M

P/E Ratio:

20.62

EPS:

1.18

Net Cash Flow:

$221.79M

1W Performance:

-0.45%

1M Performance:

+8.86%

6M Performance:

+20.51%

1Y Performance:

+4.60%

1-Day Range:

$23.65

$24.68

1-Week Range:

$23.27

$24.85

52-Week Range:

$19.05

$26.58

Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile

Name

Catalyst Pharmaceuticals Inc

Sector

Healthcare (1111)

Industry

Biotechnology (622)

Phone

(305) 529-2522

Address

355 ALHAMBRA CIRCLE, CORAL GABLES

Employee

167

Twitter

@CatalystForRare

Next Earnings Date

2024-11-06

Latest SEC Filings

CPRX's Discussions on Twitter

Compare CPRX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CPRX Catalyst Pharmaceuticals Inc	24.33	2.90B	460.48M	142.80M	221.79M	1.18
VRTX Vertex Pharmaceuticals Inc	491.47	117.98B	12.04B	3.95B	3.34B	15.33
REGN Regeneron Pharmaceuticals Inc	803.17	82.85B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	821.96	51.58B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	314.40	40.75B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.07	38.33B	4.98B	69.60M	525.67M	0.5198

Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-04-25	Initiated	Robert W. Baird	Outperform
Nov-18-24	Initiated	Stephens	Overweight
Mar-14-24	Initiated	Citigroup	Buy
Mar-07-24	Initiated	BofA Securities	Buy
Dec-21-23	Initiated	Oppenheimer	Outperform
Aug-24-22	Downgrade	ROTH Capital	Buy → Neutral
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Sep-07-18	Resumed	Piper Jaffray	Overweight
Oct-05-16	Upgrade	Piper Jaffray	Neutral → Overweight
Apr-26-16	Downgrade	Piper Jaffray	Overweight → Neutral
Sep-30-14	Reiterated	ROTH Capital	Buy
Sep-16-14	Reiterated	ROTH Capital	Buy
Sep-15-14	Reiterated	H.C. Wainwright	Buy
Oct-21-13	Reiterated	Aegis Capital	Buy
Sep-24-13	Initiated	Maxim Group	Buy
Sep-06-13	Reiterated	Aegis Capital	Buy
Apr-18-13	Initiated	Aegis Capital	Buy
Aug-27-12	Upgrade	Rodman & Renshaw	Mkt Perform → Mkt Outperform
Oct-01-09	Upgrade	Merriman	Sell → Neutral
May-29-09	Downgrade	Hapoalim	Neutral → Underperform
May-29-09	Downgrade	Merriman Curhan Ford	Buy → Sell
Dec-15-08	Initiated	Merriman Curhan Ford	Buy
Nov-28-07	Initiated	Rodman & Renshaw	Mkt Outperform
Jan-31-07	Initiated	Stifel Nicolaus	Buy
Jan-05-07	Initiated	First Albany	Buy

View All

Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News

Feb 14, 2026

What is Catalyst Pharmaceuticals Inc. s 5 year growth outlookQuarterly Profit Report & Weekly Setup with High ROI Potential - mfd.ru

Feb 14, 2026

Will Catalyst Pharmaceuticals Inc. benefit from government policy2025 Sector Review & High Accuracy Swing Entry Alerts - mfd.ru

Feb 14, 2026

Feb 12, 2026

Is Catalyst Pharmaceuticals Inc.’s growth already priced inJuly 2025 Highlights & Long-Term Capital Growth Strategies - mfd.ru

Feb 12, 2026

Block Trades: Is iShares Gold Trust impacted by rising ratesInflation Watch & Community Consensus Trade Alerts - baoquankhu1.vn

Feb 12, 2026

Feb 11, 2026

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 - GlobeNewswire

Feb 11, 2026

Catalyst Pharmaceuticals (CPRX) Investor Outlook: A Promising 41.4% Upside Potential - DirectorsTalk Interviews

Feb 11, 2026

Feb 10, 2026

Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Renewed Interest And Pocket Pivot Signal - Sahm

Feb 10, 2026

Feb 08, 2026

Allianz Asset Management GmbH Cuts Stake in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat

Feb 08, 2026

Feb 07, 2026

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Combines Strong Growth with Bullish Technical Setup - ChartMill

Feb 07, 2026

Feb 06, 2026

Catalyst Pharmaceuticals (NASDAQ:CPRX) shareholders have earned a 41% CAGR over the last five years - Yahoo Finance

Feb 06, 2026

Feb 05, 2026

What is the next catalyst for Oramed Pharmaceuticals Inc.July 2025 Sentiment & Stock Portfolio Risk Control - Mfd.ru

Feb 05, 2026

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat

Feb 05, 2026

Feb 03, 2026

Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term - Yahoo Finance

Feb 03, 2026

Feb 02, 2026